Investing.com - Lucid Capital Markets raised its price target on Palvella Therapeutics (NASDAQ:PVLA) to $212.00 from $122.00 while maintaining a Buy rating following positive Phase 2 trial results.
Get a flatter, stronger stomach at home! Try these five effective belly fat exercises that strengthen your core and burn calories. (Image: Pexels) It can be hard to find the time to hit the gym, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback